Arthur Kim Ritchey, MD

  • Vice Chair of International Affairs and Professor of Pediatrics

A. Kim Ritchey, MD is a Professor of Pediatrics and Vice Chair of International Affairs in the Department of Pediatrics. He is a pediatric hematologist-oncologist who has extensive experience caring for children with blood diseases and cancer, participates and leads clinical investigation in the field, and has mentored numerous trainees in the clinical and clinical research settings. He is the departmental representative for all aspects of international activity.

Ritchey graduated from Dartmouth College, University of Cincinnati School of Medicine, competed pediatric residency at Johns Hopkins Hospital, and fellowship training at Yale University School of Medicine. He was Chief of the Section of Pediatric Hematology/Oncology at West Virginia University School of Medicine and most recently served as the Division Chief of Pediatric Hematology/Oncology at University of Pittsburgh School of Medicine for 14 years.

Ritchey's clinical and clinical research interests span both oncology and hematology. In the field of oncology, he has served as PI of individual clinical trials and on several clinical trial study committees. He was the local PI for the Pediatric Oncology Group or Children's Oncology Group (COG) for over 25 years. He served on the NCI Pediatric Leukemia and Lymphoma Steering Committee and is Chair of the COG Data Safety Monitoring Committee for Phase 2 and 3 trials.

In the field of hematology, Ritchey has particularly focused on hemophilia. He has cared for infants and children with hemophilia for over 30 years. He initiated the Comprehensive Hemophilia Clinic at Yale New Haven Hospital and served on the Executive Committee of Region III Federally Funded Hemophilia Treatment Centers for 13 years. Ritchey is a member of the Board of Directors of the Hemophilia Center of Western Pennsylvania.

Ritchey has held important roles nationally. He was the President of the American Society of Pediatric Hematology/Oncology and served on many committees of the Society. He was the Chair of the Subboard of Pediatric Hematology/Oncology of the American Board of Pediatrics and was also appointed to its the Board of Directors.

Professional and Scientific Society Memberships

  • American Academy of Pediatrics, 1979-1998, 2012-2016
  • American Society of Pediatric Hematology/Oncology, 1981-Present
    • Program Committee, 1998-2002
      • Chairman, 1999-2001
    • Board of Trustees Member, 2000-2003, 2009-2010
    • Finance Commitee Member, 2003-2009
    • Vice-President, 2010-2012
    • President, 2012-2014
    • Immediate Past President, 2014-2016
    • Executive Committee, 2010-2016
  • American Society of Hematology, 1983-Present
  • American Society of Clinical Oncology, 1986-Present
  • Cooperative Study of Sickle Cell Disease, 1980-1990
  • Pedaitric Oncology Group (POG), 1986-1998
    • Principal Investigator, West Virginia University, 1989-1998
    • Chairman, Supportive Care Commtitee, 1989-1994
    • Chairman, Cancer Control Committee, 1990-1993
    • Core Commitee Member, Lymphoid Relapse, 1988-98
    • Chairman, Sub-committee on CNS relapse, 1992-1998
    • CCOP/Cancer Control, 1989-1996
    • Hematology/Oncology Discipline, 1989-1998
    • Member, Nominating Committee, 1994-1998
  • Region III, Federally Funded Hemophila Treatment Centers, Executive Committee, 1998-2011
  • American Board of Pediatrics
    • Certifying Exam Committee, 1998-2015
      • Chairman, 2005-2009
    • ABP Subspecialties Consortium, 2002-2009
    • ABP Board of Directors, 2012-2014
      • Executive Commitee of the Board, 2012-2014
    • ABP Foundation Board of Directors, 2012-2014
    • Subboard of Pediatric Hematology-Oncology, 2006-2012
      • Chairman, 2010-2011
      • Credentials Subcommittee of the Subboard, 2008-2011
  • Children's Cancer Group
    • Principal Investigator, Children's Hosptial of Pittsburgh, 1998-2000
    • CCG-1951 Study Committee, 1998-2000
  • Children's Oncology Group
    • Member, 2000-Present
    • Principal Investigator, UPMC Children's Hospital of Pittsburgh, 2000-2013
    • Chairman, Extramedullary Relapse Committee, 2000-2002
    • Chairman, Hematology/Oncology Discipline, 2001-2011
    • Member, Executive Committee, 2001-2011
    • Vice Chair, Cancer Control Committee, 2002-2003
    • Member, Institutional Performance Monitoring Committee, 2006-2011
    • Co-leader, Extramedullary Relapse of ALL Protocol Development, 2010-2013
    • Chairman, Data Safety Monitoring Committee A, 2013-Present
  • National Cancer Institute
    • Physician Data Query (PDQ), Pediatric Board, 1994-Present
      • Editor-in-Chief, 1997-Present
    • Pediatric Leukemia and Lymphoma Steering Commitee, 2010-2018


Education & Training

  • AB, Philosophy, Dartmouth College, 1968
  • MD, University of Cincinnati Medical College, 1972
  • Internship in Pediatrics, Johns Hopkins Hospital, 1972-1973
  • Residency in Pediatrics, Johns Hopkins Hospital, 1973-1975
  • Fellowship in Pediatric Hematology/Oncology, Yale University School of Medicine, 1977-1980

Selected Publications

Bhatia S, Landier W, Hageman L, Kim H, Chen Y, Crews KR, Evans WE, Bostrom B, Casillas J, Dickens DS, Maloney KW, Neglia JP, Ravindranath Y, Ritchey AK, Wong FL, Relling MV: 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study Blood.124(15):2345-53, 2014. PMID: 24829202

Paoletti G, Bogen D, Ritchey AK: Severe iron deficiency anemia: Still an issue in toddlers. Clin Pediatr (Phila) 53(14):1352-8, 2014. PMID: 24990367

Bhatia S, Landier W, Hageman L, Heeyoung K, Yanjun C, Sun C-L, Kronegay N, Evans WE, Angiolillo AL, Bostrom B, Casillas J, Lew G, Maloney KW, Mascarenhas L, Meza J, Ritchey AK, Termuhlen AM, Carroll, WL, Wong FL, Relling MV: Systemic exposure to thiopurines and risk of relapse in children withacute lymphoblastic leukemia. JAMA Oncology 1(3):287-295,2015. PMID: 26181173

Vrooman LM, Kirov II, Dreyer ZE, Kelly M, Hijiya N, Brown P, Drachtman RA, Messinger YH, Ritchey AK, Hale GA, Maloney K, Lu Y, Plourde PV, Silverman LB: Activity and toxicity of intravenous Erwinia asparaginase following allergy to E.coli-derived asparaginase in children and adolesscents with acute lymphoblastic leukemia. Pediatr Blood Cancer 63(2):228-33, 2016. PMID:26376459

Cooper JD, Ritchey AK: Response to treatment and adverse events associated with use of recombinant activated Factor VII in children: A retrospective cohort study. Ther Adv Drug Saf 8: 51-59, 2017. PMID:28255432

Landier W, Chen Y, Hageman L, Kim H, Bostrom BC, Casillas JN, Dickens DS, Evans WE, Maloney KW, Mascarenhas L, Ritchey AK, Termuhlen AM, Carroll WL, Relling MV, Wong FL, Bhatia S. Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. Blood 129(14):1919-1926, 2017. PMID:28153823

Landier W, Hageman L, Chen Y, Kornegay N, Evans WE, Bostrom BC, Casillas J, Dickens DS, Angiolillo AL, Lew G, Maloney KW, Mascarenhas L, Ritchey AK, Termuhlen AM, Carroll WL, Relling MV, Wong FL, Bhatia S. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and 59. Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. J Clin Oncol. 35(15):1730-1736, 2017. PMID:28339328

Wang X, Sun CL, Hageman L, Smith K, Singh P, Desai S, Hawkins DS, Hudson MM, Mascarenhas L, Neglia JP, Oeffinger KC, Ritchey AK, Robison LL, Villaluna D, Landier W, Bhatia S. Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study. J Clin Oncol. 2017 Oct 4:JCO2017747444. doi: 10.1200/JCO.2017.74.7444. [Epub ahead of print] PMID: 28976792

Oparaji JA, Rose F, Okafor D, Howard A, Turner RL, Orabi AI, Byersdorfer C, Mi Q, Ritchey K, Lowe ME, Husain SZ. Risk Factors for Asparaginase-associated Pancreatitis: A Systematic Review. J Clin Gastroenterol. 2017 Apr 3. doi: 10.1097/MCG.0000000000000827. [Epub ahead of print] PMID: 28375864

Barredo JC, Hastings C, Lu XF, Devidas M, Chen Y, Armstrong D, Winick N, Wood BL, Yanofsky R, Loh M, Gastier-Foster JM, Jorstad DT, Marcus R, Ritchey K, Carroll WL, Hunger SP. Isolated late Testicular Relapse of B-cell Acute Lymphoblastic Leukemia Treated with Intensive Systemic Chemotherapy and Response-based Testicular Radiation: A Children’s Oncology Group Study. Pediatr Blood Cancer. 2018 May;65(5):e26928. doi: 10.1002/pbc.26928. Epub 2017 Dec 29 PMID:29286562

Full Publication List via NIH PubMed »

Research Grants

Children’s Oncology Group Protocol CA180-372 A Phase 2 Multi-Center Study of Dasatanib added to Standard Chemotherapy for Philadelphia positive ALL. CHP PI: A. Kim Ritchey, MD, 1% effort; 6/12-6/18 (Closed); Total payments: $52,300; Bristol-Myers-Squibb.

A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP). CHP PI: A. Kim Ritchey, MD, 1 % effort; 12/15 – Ongoing; Total payments: $53,913; Amgen